GlassScriptPhysician profile
Karen L Babitt
NPI 1073583787
$4,262.72
in general payments reported to CMS, 2019-2025
34 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $231 · 2021: $453 · 2022: $405 · 2023: $953 · 2024: $1,061 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,465.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $942.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $466.74 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $438.72 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $366.84 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astellas Pharma US INC | $201.16 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $198.32 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $192.59 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $175.64 | 2019-2025 | |
| Amgen INC. | $151.52 | 2019-2025 | Krystexxa |
| Merck Sharp & Dohme LLC | $127.51 | 2021-2025 | Capvaxive, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $123.69 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $115.84 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.65 | 2019-2024 | Tradjenta, Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $102.00 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $78.34 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $39.20 | 2019-2023 | |
| Hikma Pharmaceuticals USA | $39.07 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $39.02 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $38.79 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.61 | 2024 | Vpriv |
| Ucb, INC. | $27.39 | 2022 | |
| Mannkind Corporation | $24.32 | 2021 | |
| Dexcom, INC. | $23.43 | 2024 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $22.44 | 2024 | Injectafer |
| Ultragenyx Pharmaceutical INC. | $22.43 | 2019 | |
| Horizon Therapeutics Plc | $21.33 | 2023 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $19.85 | 2025 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $19.24 | 2023 | Airduo Digihaler |
| Nestle Healthcare Nutrition INC. | $18.16 | 2021 | |
| Genzyme Corporation | $18.10 | 2019 | |
| Antares Pharma, INC. | $17.44 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.04 | 2021 | |
| Seqirus USA INC | $16.13 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Babitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.